Скачать или смотреть ImmunityBio Inc. (IBRX) Stock News Today: FDA Talks, Phase 2 Results & Price Target Forecast!

Stay informed on all the latest news for ImmunityBio Inc. (IBRX) stock! The stock is seeing significant volatility this week following a variety of catalysts, including positive Phase 2 glioblastoma trial results and ongoing discussions with the FDA regarding ANKTIVA's resubmission path for bladder cancer treatment.

Analysts have a "Strong Buy" consensus for IBRX, with an average price target around $10.80, and a high target of $24.00, suggesting potential upside of over 50% from its recent closing price of $6.45. The company has shown massive momentum, with a year-to-date return of over 255%.
This video covers recent news, price analysis, and future forecasts.

Queries
IBRX stock news today
IBRX stock price
IBRX share price
IBRX stock price latest
IBRX stock analysis
IBRX stock forecast
IBRX company news
IBRX stock technical analysis
Immunitybio Inc IBRX
IBRX stock price target
IBRX ANKTIVA FDA news
IBRX glioblastoma trial results
ImmunityBio share price prediction
Is IBRX a buy?
IBRX short interest